Back to GetFilings.com

(Exact Name of Registrant as Specified in its Charter)

(Address of Principal Executive Offices and Zip Code)

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirement for the past 90 days.

Yes    X            No

Number of shares outstanding of the issuer's Common Stock, par value $.01 per share, as of September 30, 2003: 8,991,443 shares.

Our discovery informatics (including: software products, post-sales support, and software consulting services) along with our discovery research (including: LeadQuest^® chemical compound screening libraries and discovery research collaborations) enable life science companies to enhance their drug discovery capabilities. We combine our resources in computer-aided molecular design, cheminformatics, chemistry research and production, with the hands-on understanding of the challenges facing pharmaceutical research scientists to deliver products and services internationally recognized for their innovation and quality. By formulating new chemical compounds or aiding our partners' design of new chemical compounds that are more likely to result in drug discoveries, we offer our customers advantages in terms of research cycle time, cost, and efficiency of research and development activities.

Tripos was formed in 1979 to commercialize software for molecular visualization, analysis, and design. In building our discovery services and software consulting capabilities, we have focused on developing an integrated suite of offerings and on achieving disciplined financial goals intended to result in positive contributions to profitability and cash flows. Our business model is based on deriving recurring revenues from our discovery informatics and discovery research business, as well as on achieving contributions from therapeutic collaborations if and when new therapeutics are developed. The following is a brief description of each area of our business:

• Discovery Informatics
• Software Products. Our SYBYL® and UNITY® software suites are the core of our discovery software offerings. These suites offer integrated tools for computer-aided molecular modeling and visualization, visual screening, combinatorial library design, data storage and analysis, and structure-activity relationships to customers in pharmaceutical, agrochemical, biotechnology and related areas of research. We offer over fifty (50) software products for these research areas. Also included in the software products category are data integration and discovery management technologies such as MetaLayerä and ChemCoreä . These technologies provide the informatics backbone to our customers' research process.
• Services. Through our collaborative software development and software consulting services, we design and build systems that enable management and analysis of the vast amounts of data generated by high-throughput technologies in structure-based genomics, proteomics, chemistry, and biology. Our consultants and programmers integrate chemistry and biology data of disparate types and sources that cannot be effectively managed on our customer's existing information technology platforms.
• Discovery Research

• Our Tripos Receptor Research laboratory, based in the United Kingdom, utilizes Tripos' discovery informatics products along with our proprietary technologies, such as ChemSpace^TM, in all of its discovery research activities.

• Products. Tripos Receptor Research produces unique, high-purity, diverse chemical compound libraries. All compounds offered for sale have a minimum purity level of 70% ensuring more reliable screening results for our customers.
• Services. We also offer compound design, synthesis, molecular analysis and a complete suite of lead discovery and lead optimization capabilities. We work with our partners in strategic chemistry research projects that may include therapeutic collaborations. These collaboration projects are focused on specific therapeutic targets in which we obtain an ownership or economic interest in the products resulting from our research.

We have a geographically diverse customer base, with over half of our revenues derived from customers outside of North America. Our worldwide sales force operates from offices in the United States, Canada, England, France, Germany and Australia, and through representatives around the remainder of the Pacific Rim. Our headquarters is in St. Louis, Missouri and our chemistry laboratory is in Cornwall, England.

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all normal recurring adjustments necessary for a fair presentation of such financial statements have been included. Operating results for the three- and nine-month periods ended September 30, 2003 are not necessarily indicative of the results that may be expected for the year ending December 31, 2003.

We recognize revenue from software licenses in accordance with Statement of Position 97-2 ("SOP 97-2"), "Software Revenue Recognition" and its update, SOP 98-4, upon product delivery, customer acceptance with all obligations fulfilled at the date of delivery, and determination that collectibility of the sale proceeds is probable. We recognize revenue from software support contracts ratably over the term of the contract, typically one to three years. In software arrangements that include rights to multiple software products, specified upgrades, software support services and/or other services, we allocate the total arrangement fee among each deliverable based on the relative fair value of each of the deliverables determined by vendor-specific objective evidence. Revenue from chemical compound sales is recognized upon delivery of the product. Hardware revenues are recognized upon shipment of the product from our vendor to the customer.

We have entered into contract research agreements and software consulting arrangements with certain customers that provide for collaboration with us in defining related software products, early access to the products, discounts on licenses for the products developed and compound library design. We recognize revenue related to contract research and software consulting agreements as contractual milestones are achieved and delivered or, absent such contractual milestones, on a completed contract basis or a percentage of completion basis. The costs of providing the services for these revenues are included in cost of sales for the periods in which the services are performed.

Within Discovery Informatics we report all software product license revenue in the Discovery Software category. All support revenue, which includes upgrades, "help-desk" and maintenance, is shown in the Support category. Fees for custom informatics or data management solutions and scientific software development collaborations are reported in the Software Consulting Services category of net sales. Our Discovery Research revenues include sales of our LeadQuest chemical compounds along with sales of chemistry design, synthesis and lead optimization activities.

We account for stock option plans under the intrinsic value method as permitted under Accounting Principles Board Opinion No. 25 ("APB 25"), "Accounting for Stock Issued to Employees", and related Interpretations. Under APB 25, generally no compensation expense is recognized because the exercise price of the options equal the fair value of the stock at the grant date.

The following table illustrates the effect on net income and earnings per share for the three- and nine-months ended September 30, 2003 and 2002 if the Company had applied the fair value recognition provisions of SFAS 123, "Accounting for Stock-Based Compensation", to stock-based employee compensation.

The provision for income taxes is computed using the liability method. The primary difference between financial statement and taxable income results from the use of different methods of computing capitalized development costs, accrued expenses, depreciation and the valuation of certain tax credits. The effective tax rate for 2003 of 79% reflects management's current estimate of the distribution of earnings among the statutory jurisdictions in which we operate and the valuation of certain tax credits and net operating losses in the U.S. and U.K. for the tax year ending December 31, 2003. In the third quarter of 2003, net income was reduced by our establishment of a $774 valuation allowance for certain deferred tax assets created by current and prior net operating losses. This non-cash charge may result in a lower effective tax rate in future periods upon the recognition of income in the jurisdictions where the deferred tax assets were created. The establishment of the valuation allowance fo r the deferred tax assets does not impair our ability to use the deferred tax assets upon achieving profitability in the related jurisdictions.

The components of comprehensive income, net of related tax, for the three- and nine-month periods ended September 30, 2003 and 2002 are as follows:

The components of accumulated other comprehensive income, net of related tax, at September 30, 2003 and December 31, 2002 are as follows:

(4)     Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the quarters and year-to-date periods ended September 30, 2003 and 2002.

Note A: For the three- and nine-month periods in 2002, weighted average shares outstanding were not adjusted for the conversion of the Series B Preferred Stock as their inclusion would have been anti-dilutive. Accordingly, the related preferred dividends were not added back to the numerator for diluted earnings per share.

Note B: For the three-month and nine-month periods in 2002 and the three-month period in 2003, weighted average shares outstanding did not include the effect of employee stock options as their inclusion would have been anti-dilutive.

For additional disclosures regarding earnings per share, see the notes to the Company's 2002 consolidated financial statements in its Form 10-K.

We maintain a physical inventory of chemical compound libraries in various states of completion. Costs associated with the manufacture of compounds are calculated using the standard cost method and are carried at the lower of cost (standard cost method approximating FIFO) or market. Compounds that are acquired from third parties are also carried at the lower of cost or market. In calculating the reserve for obsolescence, collections of compounds are reviewed for their age and

cumulative sales trends. A reserve provision is made as a component of cost of sales for each library of compounds based on their individual potential obsolescence rate (including contaminated or unsold items). If there is, in our opinion, a specific compound collection or library that is not marketable, an additional reserve provision is taken. Excess costs and costs of unsuccessful library development are expensed as identified through R&D. Raw materials include the cost of purchased starting materials (reagents) and solvents. Work in process and finished goods inventory includes the accumulated cost of compounds in production or awaiting shipment to customers under discovery research or custom synthesis contracts. Amounts for such contracts are shown separately below.

On January 29, 2002, the holder of the Series B Preferred Stock, LION Bioscience, voluntarily converted the shares into common stock and was paid the accrued dividend in cash. On February 7, 2002, LION sold all of these shares in a block trade with the assistance of a broker.

During the third quarter of 2003, revenues from Pfizer, Inc. represented 55% of total net sales. For the same period in 2002, Pfizer represented 43% of total net sales. No other customers represented over 10% of total net sales in either period. In the first quarter of 2002 we announced three separate contracts with Pfizer for multi-year worldwide licenses to our discovery software products, for a multi-year collaborative software development project around our Lithium™ technology and a $100 million four-year discovery research services project to design and synthesize exclusive compound libraries. We are in the second year of work on both the Lithium™ software development project and the $100 million four-year discovery research services project. For additional information on the Pfizer design and synthesis contract, see Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations, Results of Operations, Net sales.

We capitalize software development costs under two conditions. First, software developed for the purpose of marketing to third parties is capitalized in accordance with Statement of Financial Accounting Standard No. 86 ("SFAS 86"), Accounting for the Costs of Software to be Sold, Leased, or Otherwise Marketed. For software developed for internal use, we have adopted SOP 98-1, Accounting for the Costs of Computer Software Developed or Obtained for Internal Use. Capitalized

costs for internal use software are amortized over the estimated useful life of the technology, typically three years, while costs of products developed for sale to third parties are amortized over the lesser of the estimated sales life of the product or three years from market release.

During 2001, we made a 30-month loan to a senior vice president in the amount of $175. The loan is further described in our proxy statement for the 2003 Annual Meeting of Shareholders. The senior vice president resigned from the Company in November 2002. As of September 30, 2003 $137 remained outstanding. We continue to take actions to collect amounts that are currently in default. In the first quarter of 2003 we created a loss reserve for the entire outstanding amount due to our assessment of the collectibility of this loan.

We have existing credit facilities provided by LaSalle Bank in the form of a revolving line of credit and a mortgage loan for our corporate headquarters building. As of September 30, 2003, $3,450 was outstanding on the line of credit and a balance of $4,187 remaining on the mortgage. The credit facilities are collateralized by substantially all of our U.S. assets and stock pledges for each of the U.S. and U.K. subsidiaries. The debt facilities also require us to meet certain financial covenants, including certain coverage ratios and a capitalization ratio. In addition, we have a construction loan facility from LaSalle Bank's affiliate, ABN Amro Bank-London, to help fund our laboratory expansion in the U.K. As of September 30, 2003, the Company had not drawn funds under the construction loan facility.

The mortgage note calls for even quarterly principal payments based on a twenty-year amortization schedule. Borrowings under the mortgage are subject to a variable interest rate at LIBOR plus 2.25%. An interest rate swap agreement was entered into that fixed the interest rate at 7.40% until April 30, 2003. Interest rates paid by the Company on the mortgage since the expiration of the swap agreement have averaged just over 3.4%. The $6,000 revolving line of credit and the construction loan require quarterly interest-only payments with any remaining balances due at maturity. The line of credit carries a commitment fee of 3/8% of the unused portion of the line. Availability under the revolving line of credit is based on eligible U.S. accounts receivable. Borrowings under the revolving line of credit and the construction loan bear interest at variable rates tied to LIBOR or the bank's prime rate. The interest rate paid for borrowings during the third quarter of 2003 was 4.0%.

In October 2003, we entered into a $4,000 temporary line of credit with LaSalle Bank. This facility makes additional financing available until mid-February 2004, should it be needed to fund completion of the Company's chemistry laboratory in Cornwall, England. The incremental line of credit carries a commitment fee of 1/2% of the unused portion of the line. Borrowings under the temporary line of credit would bear interest at variable rates tied to LIBOR or the bank's prime rate.

During 2001 and again in 2002, we made in-kind investments totaling $552 in Signase, Inc., a Texas-based biotechnology company that researches cancer therapeutics. We recorded an initial write-down of $402 in the fourth quarter of 2002. Late in the first quarter of 2003, Signase advised its shareholders that it had yet to be successful in its attempt to obtain additional financing. As a result, we wrote off the remaining $150 of our investment in the first quarter of 2003. As of September 30, 2003, Signase was seeking shareholder approval to sell the company's assets. We are unable to predict whether the sale will occur or will result in proceeds to Tripos.

Also during 2001 and 2002, we invested in the TechAMP II fund administered by A.M. Pappas. The fund was renamed the A.M. Pappas Life Science Ventures II in during 2002. This fund invests in new and developing companies in the life science sector. Our investment represents approximately 2.2% of the total capital of the fund. The fund's accounting policies require it to record impairments in its assets in accordance with generally accepted accounting principles; in turn, we are required to recognize our pro-rata share of such impairments. In the first quarter of 2003, the fund managers reduced the carrying value of one of the fund's investment targets by 50%. We reflected our pro-rata share, $51, of the write-down of that investment in our first quarter financial results. In the second quarter of 2003, the fund managers determined that this investment required a further write-down to its liquidation value. Additionally, the fund managers determined that a second investment was impaired and w e recorded our pro-rata share of the full write-down. Our pro-rata share of these write-downs was $59 and was recorded in our 2003 second quarter results.

The remainder of this report may contain certain statements that are forward-looking and involve risks and uncertainties. Words such as "expects", "anticipates", "projects", "estimates", "intends", "plans", "believes", variations of such words and similar expressions are intended to identify such forward looking statements. These statements are based on current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. Among the factors that could cause actual results to differ materially from the forward-looking statements are set forth under the caption "Cautionary Statements -- Additional Important Factors to be Considered" in Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") in Tripos' Form 10-K for 2002. Tripos undertakes no obligation to update any forward-looking statements in this Form 10-Q.

The following discussion should be read in conjunction with the audited consolidated financial statements and notes thereto.

We are a leading provider of discovery chemistry, integrated discovery software products, software consulting services, and discovery research services to the pharmaceutical, biotechnology, agrochemical, and other life sciences industries. We combine information technology and scientific research to optimize and accelerate molecular research for the discovery of new products by our customers. Our products include proprietary discovery software tools to manage, analyze and share biological and chemical information; systems integration along with other software consulting services; diverse chemical libraries; collaborative and contract research for the discovery, synthesis, characterization and optimization of new chemical compounds that are active in biological systems.

We license software and support in the form of one to three-year renewable contracts for any of our over 50 software modules available for sale. The magnitude of these license fees is dependent on each customer's required usage levels, that is, the number of locations and individual users. Variations in licensing levels range from the low hundred-thousands up to several million dollars and therefore may be sufficient to impact the comparability of quarterly results.

Our integration of chemistry and biological data in the life sciences industries creates a revenue stream for enterprise software consulting services. To serve this market, we maintain a staff of specialists who use our proprietary data integration framework to configure customized solutions for data management. Revenue may be generated on a billable rate per day, or upon achievement of milestones or deliverables and is recognized as services are performed. These contracts may also generate substantial license fee revenue for our proprietary software technologies such as our MetaLayer^TM, ChemCore^TM and LITHIUM^® software. As with our discovery software products, licensing levels may range from the low hundred-thousands up to several million dollars and therefore may be sufficient to effect quarterly comparisons.

We develop and manufacture general screening compound libraries for sale to the life sciences industry. This has created the opportunity to offer follow-up discovery research services to customers for design and synthesis of focused libraries for lead optimization. We also market a comprehensive research process to our life sciences customers for rapid and cost effective discovery. This process combines advanced informatics, chemistry and third party biology services, and proprietary discovery technologies for efficient lead development, refinement, and optimization resulting in a tightly integrated process to facilitate synergies in drug discovery.

We also act as a reseller of computer hardware in conjunction with software sales. Hardware sales are generally made to facilitate integration of our software into customer research activities and are not a focus of our sales activities. We act merely as an authorized reseller and do not maintain any inventory. Accordingly, margins on these sales are relatively modest.

We license discovery software tools to customers, provide ongoing support, including upgrades selected by customers, and provide consulting services to customers that enable integration of our discovery tools to customers' discovery operations. We generally expense research and development costs associated with software enhancements and new software tools. Thus, a significant portion of

the costs associated with development and enhancement of software is accounted for as research and development and not as a cost of software sales.

Quarterly expenses include the costs of research and development for software development and new chemistry research. These expenses along with selling, marketing and general administrative expenses may rise in future periods as our company grows. Variability in quarterly expenses primarily occurs in relation to the level of revenues for sales compensation, bonuses and staffing for selling, general and administrative functions plus infrastructure growth related to our Tripos Receptor Research laboratory expansion.

In April 2002, we announced our intentions to expand our chemistry research facility in England. Our estimate of the total investment in new laboratories and equipment is $26 million less grant funding of approximately $6 million coming from the British central and regional governments over the coming two years. Over $14 million has been expended on this project through September 30, 2003. We remain on target to complete this project by early 2004 and within budget.

Our revenues and expenses vary from quarter to quarter depending upon, among other things, the timing of customers' budget processes and spending patterns, the success of our sales efforts, the lengthy sales cycle and our ability to influence customers and prospective customers to make decisions to outsource portions of their discovery process, the size of the customers' capital expenditure budgets, the ability to produce compound libraries in a timely manner, market acceptance of new products and enhanced versions of existing products, the timing of new product introductions by us and other vendors, changes in pricing policies (ours, partners and other vendors), consolidation in customer base, client involvement in decision points in contracts related to project plans, and changes in general economic and competitive conditions. In addition, we may negotiate a long-term software license contract that may, subject to certain rules of SOP 97-2 and SOP 98-4, be required to be recognized ratab ly over the life of the contract. See Note 1 of the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q for a further discussion of revenue recognition policies. A substantial portion of product-based revenues for each quarter is attributable to a limited number of orders which, if received, tend to be received toward the end of each quarter. Thus, even short delays of sales near the end of a quarter can cause quarterly results to fluctuate substantially. Our quarterly results will also be affected by the mix of revenue components. The variability of the timing of milestones, term, scope and magnitude of service-based contracts along with our ability to attract additional contracts can have a significant impact on quarterly and annual comparisons.

Net sales for the third quarter of 2003 were $12,480 compared to $11,125 in 2002, an increase of 12%. For the nine-months ended September 30, 2003, total net sales were $38,279 compared to $34,887 for the same period in 2002 which was an increase of 10%. However, because economic uncertainty continues to affect customers' decision-making, the Company believes that total revenue growth for the full year 2003 compared to 2002 will be at a lower percentage rate than in the third quarter and first nine months of the year. This view is not the result of specific developments with a

particular customer or customer prospect, but rather management's current outlook regarding near-term procurement of pharmaceutical and biotechnology research products and services.

For the three months ended September 30, 2003, discovery software and support sales increased 11% to $4,525 from $4,089 for same period in 2002. For the nine-months year-to-date, the combination of discovery software license and support revenues decreased 15% to $14,453 from $17,060 in 2002. This decrease for the year-to-date period was primarily attributable to the recording of a large wide-area network license sale in the first quarter of 2002 for the global implementation of our full software suite at Pfizer, Inc. Software consulting services revenues for the third quarter declined 50% to $686. For the nine-months ended September 30, 2003, software consulting services decreased 32% to $3,093 compared to $4,571 for the same period in 2002. This decrease is due to reduced levels of active contracts. Discovery research sales, including LeadQuest® compound li braries, accounted for $7,154 in the third quarter of 2003 and $5,290 in the same period in 2002, an increase of 35%. Year-to-date these revenues increased 61% to $20,105 from $12,502 in 2002. This increase in Discovery research business was attributed to higher levels of production on the four-year, $100 million strategic compound design and synthesis contract with Pfizer (initiated in January 2002), and value-added chemistry research work for other customers. Hardware sales decreased by 69% to $115 for the third quarter 2003 from $367 in 2002 and decreased 17% to $628 for the nine-month period ended September 30, 2003 compared to $754 for the same period in 2002 due to reduced pricing by our supplier and lower demand by customers.

As previously disclosed, in January 2002, we entered into a strategic collaboration with Pfizer to design, synthesize and purify chemical compounds. Pfizer has the right, commencing on July 1, 2003, to terminate this contract on six months' prior written notice. To date, Pfizer has not exercised its right to terminate. We cannot predict whether Pfizer will exercise this termination right in the future, or whether any termination, were it to occur, would have a material adverse effect on our financial condition or results of operations.

Net sales for the Company's activities outside of North America represented approximately 79% for both the three and nine-month periods ending September 30, 2003 compared to 72% and 62% for the same periods in 2002, respectively. Net sales in Europe increased 24% and 47% for the three and nine-month period ending September 30, 2003, and accounted for 64% and 66% of total sales, respectively. This increase was principally related to progress on the Pfizer strategic compound design and synthesis project that was contracted through our European operations. Net sales in the Pacific Rim increased by 16% for the three-month period and decreased by 17% in the nine-month period ending September 30, 2003 compared to the same periods in 2002. The Pacific Rim sales accounted for 8% and 10% of net sales for three and nine-month periods in 2003, respectively. The nine-month decrease is related to lower discovery software revenues in the region. Sales to existing customers represented 94% of total net s ales for the nine-month period ending September 30, 2003.

Cost of sales for the three-month period ending September 30, 2003 increased 26% to $5,856 compared to $4,660 for the same period in 2002. For the nine-month period ending September 30, 2003, cost of sales increased 35% to $17,820 compared to $13,177 in 2002. The increases in 2003 were due to significantly increased sales of higher cost discovery research work, primarily from the

Pfizer strategic compound design and synthesis contract. Cost of sales in 2003 for Discovery Research was adversely impacted by higher levels of outsourcing costs for certain production activities. Cost of sales as a percent of net sales was 47% and 42% for the three-month periods in 2003 and 2002, respectively. For the nine-month period in 2003, cost of sales was 47% of net sales and 38% for the same period in 2002.

Gross profit margin for the third quarter 2003 declined to 53% of total net sales versus 58% in the third quarter of 2002. For the nine-months year-to-date, gross margin percentage decreased to 53% in 2003 compared to 62% in 2002. The decrease in gross margin percent to net sales is a result of the shift in the mix from predominantly higher-margin discovery software sales toward lower-margin discovery research revenues. Year-to-date Discovery Research revenue was 53% of total net sales in 2003 compared to 36% in 2002. In addition, gross profit in the third quarter of 2003 was adversely impacted by outsourcing costs described above and the further weakening of the U.S. dollar against the British Pound Sterling as most of our Discovery Research activities are performed in Cornwall, England and billed in U.S. dollars. A portion of this impact was offset by hedging gains reflected in Other Income.

Sales and marketing expenses decreased 11% to $3,448 from $3,879 for the third quarter of 2003 and 14% to $10,475 from $12,193 for the nine-month period ending September 30, 2003 compared to the same periods in 2002. Sales and marketing expenses as a percentage of net sales were 28% and 35% for the three-month periods and 27% and 35% for the nine-month periods in 2003 and 2002, respectively. The decrease in sales and marketing spending and their percent to net sales was attributable to lower salary, commission and advertising expenses along with overall higher net sales.

Research and development expenses increased by 44% to $3,420 from $2,376 and represented 27% and 21% of net sales for the three-month periods in 2003 and 2002, respectively. For the nine-month period in 2003 research and development expenses increased by 30% to $10,295 compared to $7,893 for the same period in 2002 and represented 27% and 23% of net sales, respectively. The increase is attributable to the incremental costs to support our UK laboratory expansion, informatics product development and the lack of new software consulting contracts which results in staff working on platform technology development in lieu of billable contracts.

General and administrative expenses increased 2% to $1,815 from $1,773 for the third quarter of 2003, and represent 15% and 16% of net sales for the respective periods. Year-to-date general and administrative expenses increased 15% to $5,647 compared to $4,924 in the previous year. The increase in expense for the third quarter is principally attributable to additions to staff at our UK laboratory and significantly higher corporate insurance premiums. These items coupled with our earlier 2003 bad debt provisions (to cover $128 of outstanding receivables from two biotech accounts along with a $137 loan to a former senior executive) were responsible for the year-to-date increase in G&A expense.

Other income increased 360% to $2,658 for the third quarter in 2003 and 191% to $7,858 year-to-date compared to the same periods in 2002. This change was due to higher sales of shares of Arena Pharmaceuticals during the third quarter and first nine months of 2003 compared to 2002. We sold

277 and 127 shares in the third quarter of 2003 and 2002, respectively. For the first nine-months, we sold 1,165 and 377 in 2003 and 2002, respectively. As of September 30, 2003, 131 shares remain on-hand. Other income for the third quarter of 2003 also included a gain on the mark-to-market of hedge instruments used to protect against foreign currency exchange exposures on the $100 million Pfizer compound design and synthesis contract along with the translation of foreign net assets into U.S. dollars. We hedge portions of this contract as we are paid in U.S. dollars while costs incurred at our laboratory are in British Pounds. These hedge instruments are reflected in our Consolidated Balance Sheets as part of our Marketable Securities while movement in the value of the instruments themselves is reflected as part of Other Income in our Consolidated Statement of Operations. The value of the hedge instruments is based on the relationship of the underlying currencies and is therefore susce ptible to slight movements in market conditions.

Income tax expense was $1,501 for the nine-month period ending September 30, 2003, which represents an effective tax rate of 79%. For 2002, the income tax benefit was $126, a 21% effective rate. The 79% effective tax rate for 2003 reflects management's current estimate of the distribution of earnings among the statutory jurisdictions in which we operate and the valuation of certain tax credits and net operating losses in the U.S. and U.K. for the tax year ending December 31, 2003. In the third quarter of 2003, net income was reduced by our establishment of a valuation allowance against deferred tax assets created by current and prior net operating losses. This non-cash charge may result in a lower effective tax rate in future periods upon the recognition of income in the jurisdictions where the deferred tax assets were created. The establishment of the valuation allowance for the deferred tax assets does not impair our ability to use the deferred tax assets upon achieving profitabil ity.

Net cash used in operations in 2003 was $2,094 arising from net income of $399, that included a pre-tax gain of $6,101 from the sale of shares of Arena Pharmaceuticals common stock, decreases in trade accounts receivable of $8,585 and notes receivable of $547 along with depreciation and amortization of $2,194 and $336 respectively and an increase in deferred taxes of $1,443, which were offset by a decrease in accounts payable and accrued expenses of $785, appreciation of foreign currency hedging instruments of $676, a decrease in deferred revenue of $4,449 and increases in inventory of $2,822. For the nine-month period ending September 30, 2002, net cash used in operations was $466 primarily due to net loss of $471, that included a pre-tax gain of $2,409 from the sale of shares of Arena common stock, and decreases in trade accounts receivable of $7,506, an increase in deferred revenue of $876 along with depreciation and amortization of $1,160 and $553 respectively, which were offset by a decrease in accounts payable and accrued expenses of $6,093 along with increases in prepaid expenses of $999 and inventory of $784. The principal differences in cashflow from operations, year over year, are related to changes in net income, higher collections of accounts receivable, additional depreciation on equipment in our laboratory expansion, additional inventory produced for our $100 million compound contract with Pfizer, lower amounts of deferred costs for software consulting contracts and the recognition of revenue on contracts in which revenue was previously deferred.

Cash provided by investing activities in 2003 was $806 generated principally from the proceeds of the sale of Arena shares of $8,071 which also funded acquisitions of capital expenditures of $6,301, investment in capitalized software development of $810 and A.M. Pappas Life Science Ventures II of $154. Cash used in investing activities during 2002 were for property and equipment acquisitions of $3,456, net investments in Signase, Inc. of $500, A.M. Pappas's Life Science Ventures II fund of $463, and capitalized development costs for our ChemCoreÔ technology of $1,131 that were partially offset by the $3,051 of gross proceeds from the sale of Arena shares.

For the first nine-month period in 2003, the net cash provided by financing activities was $4,482, consisting of capital lease arrangements totaling $4,913, borrowing under our line of credit of $3,450 and proceeds from the issuance of shares under our employee stock plans of $543 offset by payments on long-term debt and capital leases of $4,424. For the same period in 2002, cash used in financing activities included the payment of accrued dividends of $892 upon the conversion of the Series B Preferred Stock by LION Bioscience and the reduction of outstanding debt by $1,035 offset by proceeds from the exercise of employee stock options and issuance of shares from our employee stock purchase plan of $1,782.

We believe that with our current working capital of $20,845, together with expected cash flows from operations, availability under our $6 million line-of-credit and $4 million temporary line of credit from LaSalle, a $2.5 million construction loan facility at ABN-Amro Bank-London, grants from the UK central and local governments, capital and operating leases, and other available forms of financing and/or capital, if necessary, we will be able to meet our liquidity needs and capital expenditure requirements for the next twelve months. See "Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources", "Cautionary Statements - Additional Important Factors to be Considered" and Note 11 of the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2002 for a discussion of the credit facilities available to us. Due to the capital needs inherent to our business and despite current cap ital markets uncertainties, we may decide to seek additional financing to support our long-term objectives to enhance product development, expand existing markets and enter new markets, expand our chemistry research laboratories, or fund participation in new therapeutic collaborations. In making decisions regarding access to additional capital, we will consider the availability and terms of financing alternatives, as well as our objective to maintain financial flexibility to support planned and opportunistic growth of our business. Additional capital may be in the form of equity or debt securities, and may be raised in public offering or private placement transactions.

Item 1.     Legal Proceedings

          On or about July 24, 2003, the Company and two of its executive officers were sued in federal district court in St. Louis, Missouri on behalf of purchasers of the Company's common stock during the first half of 2002. The class action suit alleges that statements made by the Company in press releases and other public disclosures contained materially false and misleading information in violation of the federal securities laws. The Company strongly believes that that these assertions are without merit. As with any litigation, it is impossible to provide an accurate assessment of the likelihood or the extent of any liability arising from this matter. The Company expects that over at least the next two quarters, it will incur expense to investigate these allegations and defend itself.

Item 2.     Changes in Securities

          None

Item 3.     Defaults upon Senior Securities

          None

Item 4.     Submission of Matters to a Vote of Security Holders

Item 5.     Other Information

          None

Item 6.     Exhibits and Reports on Form 8-K

          (a) List of Exhibits

31.1 Section 302 Certification of the Chief Executive Officer

31.2 Section 302 Certification of the Chief Financial Officer

32.1 Written Statement of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

          (b) No reports on Form 8-K were required to be filed during the period from July 1, 2003 to September 30, 2003.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.